Home page

Read about the BACKRACK and more on THE LUKLINSKI' SPINE CARE site!

The Patented Back Rack - Brings instant relief from back pain!

Telephone: +44(0)207-631-3067 Emergencies: +44(0)7710-901140
THE LUKLINSKI' SPINE CLINIC
Suite 17, Milford House - 7 Queen Ann St. (off Harley St.), London, W1G 9HN
Established 1969 - over 40 years experience in treating spinal disorders
Share your experience at our DISCUSSION FORUMS Polish version Arabic version
Mr. Luklinski
LinkedIn Profile >>

You are visitor no. 557635
since 1st Jan 2011

Site realised by G. Marotta

Hosting by Memset Dedicated Servers

Free Page Rank Tool

Powered by

Stanford orthopedist reveals problems with Medtronic spinal fusion product


by Ruthann Richter ( Orthopedics Stanford News )



June 28, 2011



During the course of this past year, Stanford orthopedist Eugene Carragee, MD, and his colleagues have done an extensive review of the data on a commonly used spinal fusion product and have found it causes vastly more complications than reported in early industry-sponsored studies. Their review (.pdf), published in today’s The Spine Journal (which Carragee edits) found the complications, including male sterility, infection, bone and nerve problems and possible increased cancer risk, were at least 10 to 50 times greater than originally reported. The authors of the early studies, who reported virtually no adverse effects, received many millions of dollars from the product manufacturer, Medtronic, Inc., the review found.

"If there weren't millions of dollars riding on it, this would be a dry discussion on the appropriate use of statistics and methodology," Carragee, a professor of orthopedic surgery, told me. "The problem is in the last 10 years, between $3 billion and $5 billion has been spent on this product, and it's not clear what benefit has been achieved, compared with how many patients have been harmed by it. The industry estimate of harm is simply wrong."

The review of the data, widely reported in the media, already has triggered a Congressional investigation, with the Senate Finance Committee requesting that Medtronic turn over all documents related to complications from the product, including communications with doctors who conducted the early trials. The product, a bioengineered protein known as rhBMP-2, is marketed under the brand names Infuse and Amplify.

Exposing these issues represents a bold move by Carragee, who is taking on an extremely powerful industry. But Carragee, who has served with the U.S. military in Iraq and elsewhere, says he's just doing his job.

"This should be the bread and butter of what clinical publications do, which is critically evaluate the evidence and create a dialogue about the advantages and disadvantages of treatment," he said. "It only appears courageous because some others haven't done it."


For more on this article click here...